PRLD - Prelude Therapeutics: Scientifically Interesting Oncology Company With Preclinical Data

2024-02-02 19:01:21 ET

Summary

• Prelude Therapeutics once produced positive clinical data from a now abandoned program.
• The company's current lead candidates are PRT3789, a SMARCA2 inhibitor, and PRT2527, a CDK9 inhibitor, both in phase 1 trials.
• Both programs have early preclinical data and look scientifically interesting.
• However, they are too early to merit an investment right now, although they bear watching.

Prelude Therapeutics ( PRLD ) is an early stage developer of cancer therapeutics. In 2022, their lead candidate, and the one program with efficacy data, used to be PRT811. PRT811 is a PRMT5 inhibitor which ran a phase 1 trial in solid tumors, including glioma and splicing mutated uveal melanoma, where it saw some positive data. This data was as follows:

In the Phase 1 trials for PRT543 and PRT811, both molecules were generally well tolerated. In the PRT811 clinical trial, a total of 82 patients across multiple tumor types were enrolled in dose escalation and expansion, of whom 57 had glioma or uveal melanoma. Out of 38 glioma patients (16 IDH+ and 22 IDH-), two complete responses were observed in IDH+ glioma. These responses remain ongoing for 62 and 21 weeks, respectively. In addition, out of 19 uveal melanoma patients (8 SPLC+ and 11 SPLC-), one confirmed partial response (duration of response of 42 weeks) and a second ongoing unconfirmed partial response were observed, both in patients who were splicing positive.

For further details see: